Brainspark PLC
15 August 2002
15th August, 2002
BRAINSPARK PLC
('Brainspark' or 'the Company')
Loan to Infusion S.p.A. ('Infusion')
Brainspark announces that, following the announcement made on 26th July, 2002
regarding the potential acquisition of a number of portfolio investments held by
Infusion, it made a loan of £1 million to Infusion on 8th August 2002. The loan,
which is repayable in full on the first anniversary of its draw down, bears
interest at fixed rate of 5.5 per cent. and is secured by a charge over a
portfolio asset of Infusion which has been independently valued at a figure in
excess of the amount of the loan.
AISoftware S.p.A. ('AIS') owns 65.5 per cent. of the issued capital of
Brainspark and 99.9 per cent. of the issued capital of Infusion. Accordingly,
the loan is classified as a related party transaction under the AIM rules.
The directors of Brainspark who are independent of AIS consider, having
consulted with the Company's nominated adviser, that the terms of the
transaction are fair and reasonable as far as Brainspark's shareholders are
concerned.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.